Status:

TERMINATED

Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98

Lead Sponsor:

ETOP IBCSG Partners Foundation

Conditions:

Breast Cancer

Osteoporosis

Eligibility:

FEMALE

30+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Studying samples of fingernails in the laboratory from patients with breast cancer may help in evaluating bone health in postmenopausal women undergoing hormone therapy for breast cancer. ...

Detailed Description

OBJECTIVES: Primary * Compare the effects of tamoxifen vs letrozole on the chemical properties of fingernails by Raman spectroscopy in postmenopausal women with breast cancer undergoing adjuvant hor...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Enrolled on protocol IBCSG-1-98
  • Currently receiving (i.e., have not yet completed) 5 years of treatment with tamoxifen or letrozole and expected to receive ≥ 6 months of additional treatment on protocol IBCSG-1-98
  • No recurrent breast cancer or second primary cancer
  • No known bone disease (including osteomalacia or osteogenesis imperfecta)
  • Hormone receptor status
  • Estrogen and/or progesterone receptor positive tumor
  • PATIENT CHARACTERISTICS:
  • Female
  • Postmenopausal
  • No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases
  • No malabsorption syndrome or clinically relevant vitamin D deficiency
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • More than 1 year since prior and no concurrent anticonvulsants
  • More than 6 months since prior and no concurrent corticosteroids at doses \> the equivalent of 5 mg/day of prednisone for \> 2 weeks total
  • No prior or concurrent sodium fluoride at daily doses ≥ 5 mg/day for \> 1 month
  • More than 12 months since prior and no concurrent anabolic steroids
  • More than 6 months since any prior drug for the prevention of osteoporosis (excluding calcium or cholecalciferol \[vitamin D\])
  • Concurrent warfarin allowed provided duration of treatment is no more than 4 weeks

Exclusion

    Key Trial Info

    Start Date :

    April 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 1 2007

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT00899288

    Start Date

    April 1 2005

    End Date

    July 1 2007

    Last Update

    July 27 2012

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.